Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Liquid Biopsy Cell-free DNA Biomarkers in Patients With Oligometastatic Colorectal Cancer Treated by Ablative Radiotherapy.

Anticancer research - 1 Feb 2021

Nakamura Masaki, Kageyama Shun-Ichiro, Seki Masahide, Suzuki Ayako, Okumura Masayuki, Hojo Hidehiro, Motegi Atsushi, Akimoto Tetsuo

Abstract excerpt

BACKGROUND/AIM: To investigate the usefulness of cell-free DNA (cfDNA) in patients with oligometastasis. PATIENTS AND METHODS: This study included oligometastatic colorectal cancer (CRC) patients who underwent ablative irradiation using stereotactic body radiotherapy or proton beam therapy for metastatic lesions at a single institution. cfDNA was purified from the plasma of pretreated patients and gene mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to High-Throughput Nucleotide Sequencing

Share to Liquid Biopsy

Share to Neoplasm Metastasis

Share to Radiosurgery

Share to Survival Analysis

Source

Identifiers

PMID: 33517288
DOI: 10.21873/anticanres.14835

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Liquid Biopsy Cell-free DNA Biomarkers in Patients With Oligometastatic Colorectal Cancer Treated by Ablative Radiotherapy.PMID 33517288Read ↗

Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular CarcinomaSemantic proximity Read ↗

A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot studySemantic proximity Read ↗

Clinical utility of circulating cell-free DNA in advanced colorectal cancer.Semantic proximity Read ↗

High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment.Semantic proximity Read ↗

The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer.Semantic proximity Read ↗

Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy.Semantic proximity Read ↗

Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study.Semantic proximity Read ↗

Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.Semantic proximity Read ↗

Two-point-NGS analysis of cancer genes in cell-free DNA of metastatic cancer patients.Semantic proximity Read ↗

The amount of circulating DNA and the presence of TP53 mutations in plasma predict clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIsSemantic proximity Read ↗

Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.Semantic proximity Read ↗

Diagnostic and Prognostic Value of Circulating Cell-Free DNA for CholangiocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.